Myeloma Patients Europe (MPE)’s Post

A groundbreaking study has been published in the Journal of Hematology and Oncology, shedding light on an intriguing medical phenomenon. Titled "Acute Onset Symptomatic Polycythemia Vera," this research delves into the complexities of myeloproliferative neoplasms (MPNs), particularly focusing on a case where polycythemia vera (PV) manifested dramatically post-splenectomy. Key Takeaways: PV, a chronic myeloproliferative neoplasm, often evolves slowly and insidiously. This study presents a unique case where PV was masked by a low-grade lymphoma until it presented acutely after a splenectomy. Despite not meeting the diagnostic criteria initially, molecular confirmation of PV was made a year later due to persistent clinical features. The findings underscore the importance of considering "acute onset" MPNs post-splenectomy, urging for a more molecular investigative approach to avert serious complications. 🔬 For a detailed exploration of this intriguing case and its implications, dive into the full article here: https://lnkd.in/gwuznmwU Stay informed, stay curious! 💡 #Research #MedicalScience #MPN #PV #AcademicDiscovery

We are excited to announce the initiation of two clinical studies evaluating ST-067, our decoy-resistant IL-18, in hematologic cancers.   The first study will assess ST-067 in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and the second will evaluate ST-067 in combination with teclistamab (TECVAYLI®) in patients with relapsed/refractory multiple myeloma.   These studies represent an important step forward in expanding the therapeutic potential of our platform and this upcoming week, we look forward to presenting preclinical data at the 2024 American Society of Hematology Annual Meeting demonstrating the therapeutic activity of ST-067 in hematologic malignancies .   Read the full press release: https://lnkd.in/e__zWHsv   #hematology #clinicaltrials #ASH24

📣 NEXT UP‼️ "Navigating the Complexities and Controversies of Integrative Molecular Strategies in Oncology” sponsored by GenomeWeb and Precision Medicine Online ✨This webinar is Part 2 of a two-part molecular tumor board Spring series: https://lnkd.in/eG-vUduY. If you missed Part 1 (5/7), it’s now available on-demand!! 🗓️: Thursday, May 16th 🕐: 1-2 pm EST 💻 REGISTER HERE: https://lnkd.in/eJYQkpJs The advent of precision oncology has transformed the therapeutic landscape for patients, presenting a paradigm shift from one-size-fits-all approaches to individualized treatment strategies. This presentation recognizes the intricate balance between the potential of various assays to guide treatment decisions and the controversies surrounding their interpretation and clinical utility. We highlight the critical importance of Variant Allele Frequency (VAF) as a biomarker for tumor burden and treatment response, as well as explore the burgeoning field of Molecular Residual Disease (MRD) assays with a focused lens on their application in solid tumors. In addition, the concurrent application of tissue-based and liquid-based Next-Generation Sequencing (NGS) testing represents a cornerstone in the evolution of diagnostic modalities. By weaving together the threads of sequencing, VAF, and MRD assays, our presentation aims to feature the synergy of these technologies in advancing precision oncology, while acknowledging the challenges and debates that shape this dynamic field. Clarified Precision Medicine Howard McLeod Derrick Haslem Ben Kong Trevor Christ

I just had the pleasure of reading through the latest 3-4 Edition of 𝐎𝐧𝐤𝐨 𝐍𝐞𝐰𝐬 𝐀𝐮𝐬𝐭𝐫𝐢𝐚 over the weekend, and I couldn’t be more thrilled with the incredible content we've put together! Being a part of the Springer Medizin Österreich team that brings this publication to life is truly rewarding.📚💡 This edition is packed with insightful articles and updates on critical topics such as the management of side effects in immuno-oncology, the latest advancements in Antibody-Drug Conjugates (#ADCs), highlights from the #ASCO Congress, and important updates from the #ÖGHO (Austrian Society of Hematology & Medical Oncology). In addition to the insightful articles and updates, we also had the privilege of conducting #interviews with leading experts in the field.🔍🎙️ Our mission with 𝐎𝐧𝐤𝐨 𝐍𝐞𝐰𝐬 𝐀𝐮𝐬𝐭𝐫𝐢𝐚 is to keep healthcare professionals informed and supported with the latest 𝒓𝒆𝒔𝒆𝒂𝒓𝒄𝒉 findings, clinical study results, and advancements in cancer treatment. These publications are a testament to our commitment to enhancing medical knowledge and improving patient care.📈💊 #OnkoNewsAustria #Oncology #Hematology #MedicalResearch #HealthcareInnovation #Immunooncology

Gates Institute member Manali Kamdar, MD first-authored their preliminary data using CD19x22 for non-Hodgkin Lymphoma at the American Society of Hematology (ASH) Conference. This groundbreaking innovation using two chimeric antigen receptors (CARs) in a single delivery vessel is a leading development in the field of CAR T-cell therapy. Additional authors from the Gates Institute include Executive Director Terry Fry, MD, Michael Verneris, MD, Navin Pinto, MD, Andrew Roth, Ph.D., and Cheri Adams, MSHS, RN, RAC. Congratulations to all of the exceptional authors from the University of Colorado Anschutz Medical Campus on this impactful publication! Read the abstract here: https://shorturl.at/2HV7v

In a recent presentation at the 2024 ASH conference, Dr. Valérie de Haas from the Princess Máxima Center for Pediatric Oncology shared groundbreaking results from the CSF-FLOW sub-study, part of the ALLTogether1 trial. This study focused on improving patient stratification in central nervous system (CNS) acute lymphoblastic leukaemia (ALL) through cerebrospinal fluid flow cytometry (CSF-FCM). Dr. de Haas highlighted how CSF-FCM provides a more sensitive and specific approach than traditional cytology, enhancing CNS relapse risk prediction. Despite its promise, she emphasized the need for careful standardization of sample volumes, analysis techniques, and protocols before CSF-FCM can be widely adopted as a clinical tool. The study's findings are a step forward in refining the accuracy of CNS staging, particularly for CNS2 patients, and could lead to better prognostic algorithms for future treatment. The results were discussed in the "Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease" session, which explores cutting-edge research in hematology.

#EHA2024 Data: Wugen presents positive Phase 2 results for WU-CART-007. During today’s oral presentation at the European Hematology Association (EHA) 2024 Hybrid Congress, researchers shared positive Phase 2 results for our investigational allogeneic, off-the-shelf anti-CD7 CAR-T therapy in patients with relapsed/refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL). Learn more about what these WU-CART-007 findings could mean for patients with hard-to-treat blood cancers: https://bit.ly/4aXdRi4 #celltherapy #research #biotechnology #WashU

Please join us for this free webinar series about #PrecisionOncology!

Spotlight on Experts at the 66th American Society of Hematology Annual Meeting & Exposition 2024 🌟 The 66th American Society of Hematology (ASH) Annual Meeting, held from December 7–10, 2024, in San Diego, California, gathers world-renowned hematology experts to showcase groundbreaking research and innovations. Here are just a few distinguished names contributing to this prestigious event: ✅ Dr. Richard M. Stone: Sharing insights on Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) during key sessions. ✅ Dr. Nitin Jain: Discussing advancements in chronic lymphocytic leukemia (CLL) at the "ASH 2024 Comes to You!" webinar. ✅ Dr. Catherine Diefenbach: Presenting the final analysis of venetoclax in combination therapies for high-risk B-cell lymphoma. ✅ Dr. Gilles Salles: Delivering a five-year analysis of the POLARIX study, emphasizing advancements in lymphoma treatment. This global event highlights remarkable progress in hematology, fostering collaboration and innovation for better patient outcomes. 📢 Stay tuned for updates! We’ll be sharing highlights, expert insights, and key takeaways from the conference on #MediaMedic . Don’t miss out on the latest developments! #ASH2024 #Hematology #MedicalInnovation #MediaMedic #OncologyFrontier

Takeda Türkiye emphasizes the importance of early diagnosis in Multiple Myeloma, a treatable cancer in which early diagnosis and appropriate treatment can improve patients' quality of life. Takeda Türkiye has created the website, www.yolculugumm.com to raise awareness about early diagnosis. Omur Mangaloglu, General Manager of Takeda Türkiye, shared his views: "At Takeda, we attach great importance to research in the field of oncology. Our goal is to improve the quality of life for cancer patients and expand treatment options. In line with this, we conduct R&D studies covering a wide range from hematologic cancers to solid tumors. Additionally, we collaborate with researchers to discover and develop treatment options through clinical trials." "On the Yolculugumm website, we have created two separate sections, one for those who want to learn about the disease and another for healthcare professionals. The section is designed for healthcare professionals, especially Turkish hematologists, and serves as a digital library where they can access content on the latest developments in multiple myeloma treatment," he added. #Hematology #MultipleMyeloma #EarlyDiagnosis #TeamTakeda #TakedaTürkiye #Takeda #WhereScienceIs